GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.
IPO Year:
Exchange: NASDAQ
Website: geovax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | $15.00 | Buy | Alliance Global Partners |
| 7/16/2024 | $20.00 | Buy | ROTH MKM |
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia (CLL). Based on the interim analysis of immune responses from the patients enrolled to date, the DSMB determined that, while the mRNA control arm of the study failed to meet the prede
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Senior GeoVax management will also host one-on-one meetings with registered attendees. Panel Details: Title: Innovative Therapies for Solid Tumors Presenter: David Dodd, Chairman & CEO Date/Time: October 9, 2024, 12:30 pm ET If you are interested in arranging a 1x1 me
MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2 - September 26, 2024 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go bac
MIAMI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-82
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events: H.C. Wainwright 26th Annual Global Investment Conference Speaker: David Dodd, Chairman & CEO Date/Time: September 9, 2024 at 7:00 a.m. ET Location: Lotte New York Palace Hotel, New York, NY Webcast Link: H.C. Wainwright Webcast Title: GeoVax Corporate Update Senior GeoVax management will host one-on-one meetings with registered attendees. If interested in meeting with management at
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company's common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 975,610 shares of common stock. The warrants have
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (NASDAQ:GOVX) ("GeoVax Labs" or the "Company"), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Now Is Not the Time to Monkey(pox) Around." The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August 23, 2024. To register to join the complimentary event, please visit the Tribe Public LLC w
MIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteM
Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00
ROTH MKM initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $20.00
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
424B3 - GeoVax Labs, Inc. (0000832489) (Filer)
424B3 - GeoVax Labs, Inc. (0000832489) (Filer)
424B3 - GeoVax Labs, Inc. (0000832489) (Filer)
424B3 - GeoVax Labs, Inc. (0000832489) (Filer)
424B3 - GeoVax Labs, Inc. (0000832489) (Filer)
10-Q - GeoVax Labs, Inc. (0000832489) (Filer)
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology. Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development
First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear
Dr. Morgan Brings Extensive COVID-19, Medical and Healthcare Management Expertise ATLANTA, GA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it has appointed Jayne Morgan, M.D., to its Board of Directors. Dr. Morgan is an accomplished and forward-thinking healthcare management executive and research leader with extensive expertise in complex hospital and corporation navigation, as well as leadership in COVID-19 management, community engagement, crisis mitigation, health equity and clinical trials. "Dr. Morgan has spe
Operational Resources Strengthened to Support Company Growth and Development Atlanta, GA, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of John W. Sharkey, PhD to serve as Vice President, Business Development. Dr. Sharkey brings over 30 years of experience in the pharmaceutical and medical device industry, with specific expertise in executive management, business development, pharmaceutical and medical device development, regulatory affairs, manufacturing and business operations covering multiple therapeutic segment
Operational Resources Strengthened in Support of Ongoing Phase 2 Clinical Trials for COVID-19 and Advanced Head & Neck Cancer ATLANTA, GA, March 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced recent key staff appointments and changes Jeffrey Welch has been appointed to serve as Head, Process Development and Manufacturing Operations (consultant). In this role, Jeff will provide oversight and direction to enhance GeoVax's manufacturing capacity of MVA-related products, a key element in advancing the Company's current and upcoming clinical developm
Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company's Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections. His progressive clinical research experience began in 1981 at Fort Detrick, Frederick, MD, United States, where he held a variety of leadership positions in virology, immunology, preventive medicine, an
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
EF Hutton analyst Jason Kolbert initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Target of $18.
SILO: 143% | Silo Pharma Obtains Exclusive Global License To Develop, Manufacture, And Commercialize Its Alzheimer's Drug GOVX: 35% | Roth MKM Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $20 CFB: -12% | CrossFirst Bankshares shares are trading lower. The company reported Q2 financial results.
Roth MKM analyst Jonathan Aschoff initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Target of $20.
Geovax Labs's (NYSE:GOVX) short percent of float has risen 143.33% since its last report. The company recently reported that it has 109 thousand shares sold short, which is 4.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest i
HC Wainwright & Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:GOVX) with a Buy and maintains $8 price target.
GeoVax Labs, Inc. (NASDAQ:GOVX) shares are trading higher Thursday on continued momentum from last week. What To Know: GeoVax Labs received a BARDA Project NextGen award to conduct a study evaluating its COVID-19 vaccine candidate GEO-CM04S1. According to Yahoo Finance, GeoVax will sponsor a Phase 2b study, containing 10,000 participants, to compare the efficacy and safety of GeoVax’s novel vaccine to a already FDA approved mRNA COVID-19 vaccine. The monetary award to GeoVax, which will support necessary preparations for the clinical trial, is about $24.3 million. The award may increase later to a maximum of $45 million. BARDA will fund the execution of the clinical trial separat
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call DetailsDomestic: (800) 715-9871International: +1 (646) 307-1963Conference ID: 3852178Webcast: https://edge.media-server.com/mmc
Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin®, targeting advanced head and neck cancer Catalyst-rich 2024 with data readouts planned throughout the year Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023. "2023 marked an
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2023 financial results on Thursday, February 29, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Dial-in numbers: Domestic: (800) 715-9871International: +1 (646) 307-1963Conference ID: 3926207 Webcast:A
Significant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cancer Conference showing safe administration and tumor reduction Multi-Product License Secured for ProBioGen's AGE1.CR.pIX® suspension cell line to enhance manufacturing capabilities of MVA-based vaccine portfolio Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announc
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Dial-in numbers:Domestic: 800-715-9871International: 646-307-1963Conference ID:
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report second quarter 2023 financial results on Wednesday, August 9, 2023, after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management's prepared remarks, there will be a Q&A period for analysts and others. Wednesd
ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management's prepared remarks, there will be a Q&A period for analysts and others. Thursday, May 4, 2023, 4:30 PM ETDomestic: 800-715-9871International: 646-307-1963C